<DOC>
	<DOCNO>NCT02250118</DOCNO>
	<brief_summary>Metastatic pleural effusion common complication late-stage cancer reduce quality life survival patient . The survival patient recurrent pleurisy uncontrolled local systemic treatment le 6 month . It important develop specific therapy improve quality life survival patient metastatic pleurisy . Bevacizumab monoclonal anti vascular endothelial growth factor ( VEGF ) proven effective many indication oncology . Vascular endothelial growth factor ( VEGF ) angiogenic factor increase endothelial permeability . It play central role many tumor epithelial origin . In context , legitimate ask whether antiangiogenic target VEGF may effective patient metastatic pleurisy decrease local blood supply over-permeability . No study interest intra-pleural pharmacokinetics monoclonal antibody predictive prognostic biomarkers metastatic pleural effusion . The investigator believe intrapleural administration bevacizumab reduce pleural vasculature permeability . It neutralize VEGF present pleural fluid reduce replenishment effusion due prolong half-life 21 day . The investigator therefore propose phase I study determine maximum tolerate dose recommend dose phase II , study pharmacokinetics intrapleural bevacizumab administer implantable device evacuate symptomatic metastatic pleurisy part mammary carcinoma . The VEGF intrapleural level serum study time new puncture . Dyspnea evaluate well impact quality life .</brief_summary>
	<brief_title>Intrapleural Bevacizumab After Pleural Drainage Context Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Patient histologically document pleural effusion type breast carcinoma exudate identify cause . In absence positive cytology , ensure cause patient 's history may explain effusion . 2 . Unilateral bilateral malignant pleural effusion require drainage one side . 3 . Patient present indication pleural implantable device , mean require least one pleural drainage . 4 . Patient age 18 year old without measure legal protection 5 . Subject female male 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) ≤ 2 7 . Expected life span &gt; 2 month 8 . Corticosteroids authorize start less 15 day enrollment dose modification allow treatment 9 . Adequate biological function 14 day inclusion : Haemoglobin ≥ 8 g/dl ( transfusion authorize ) Neutrophil count ( ANC ) ≥ 1000/mm3 Platelet count ≥ 100 000/mm3 International Normalized Ratio ( INR ) ≤ 1.5 and/or Prothrombin Ratio ( TR ) ≥ 70 % Partial Thromboplastin Time ( PTT ) ≤ 1.5 Aspartate Aminotransferase Test ( AST ) , Alanine Aminotransferase Test ( ALT ) , GammaGlutamyl Transpeptidase ( GGT ) , Alk Phos ≤ 3 time Unit Line Number ( ULN ) , bilirubin ≤ 40 μmol/L Lactate Dehydrogenase ( LDH ) ≤ 1,5 time ULN Albumin ≥ 28 g/dL Creatinine clearance ≥ 45 mL/min accord Modification Diet Renal Disease formula ( MDRD ) Proteinuria ≤ 1g/dL absence tract infection 10 . Cardiac Function satisfactory : Left Ventricular Ejection Fraction ( LVEF ) determine myocardial scintigraphy echocardiography 11 . Females childbearing potential must take acceptable method birth control complete duration treatment serum pregnancy test must negative inclusion . Men must agree use condom partner child bear potential 12 . Patient receive social security system 13 . Signed inform consent 1 . Pregnant lactate woman childbearing potential refusing method birth control 2 . Transudative pleural effusion : pleural protein &lt; 30 g/L and/or Light 's criterion pleural protein indicative . Light 's criterion follow ( diagnosis transudative ) : Pleural protein/serum protein ratio &lt; 0.5 Pleural LDH/serum LDH ratio &lt; 0.6 Pleural LDH &lt; twothirds upper limit normal serum LDH 3 . Purulent pleural effusion . 4 . Macroscopically haemorrhagic pleural effusion . 5 . Bilateral metastasis pleurisy require puncture side . 6 . Any co morbidity consider incompatible participation study , accord investigator , particularly : untreated infectious disease , chronic respiratory insufficiency , chronic renal insufficiency , Child Pugh B C , hepatocellular insufficiency ; chronic heart failure control appropriate medical treatment . 7 . Contraindications intrapleural administration bevacizumab : Noncontrolled arterial venous thromboembolism Major surgery previous month plan study Known , non treat brain metastasis Known hypersensitivity bevacizumab one excipients Hypersensitivity Chinese hamster ovary cell ( CHO ) product human recombinant humanize antibody Intravenous administration bevacizumab plan underway usual cancer treatment ( ≥ 3 week wash intrapleural injection ) Radiotherapy include lung field concern since administration product end study . 8 . Diagnosis second malignancy within last 5 year , except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; 3 year . 9 . Patients ca n't participate another clinical trial another experimental anticancer drug therapy simultaneously 90 day . No exclusion period required end trial visit . 10 . Impossibility follow calendar exam geographic , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>pleural</keyword>
	<keyword>effusion</keyword>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
</DOC>